Hospitalization Burden by Age and Comorbidity in Adults With Recurrent Clostridioides difficile Infection: An Exploratory ECOSPOR III Analysis (ACG 2026) - Aug 29, 2026 - Abstract #P1296; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); " ECOSPOR III was a phase 3, randomized, double-blind trial of fecal microbiota spores, live-brpk vs placebo for prevention of rCDI. Adults with â¥3 CDI episodes in 12 months, toxin-positive CDI, and symptom resolution after 10â21 days of vancomycin or fidaxomicin were followed for 24 weeks... The ITT population included 182 patients (98.9% managed as outpatients); mean age was 65.6 years and mean age-adjusted CCI was 4.1â4.2 across treatment arms. Through week 24, 36 patients (19.8%) were admitted to the hospital for any reason, including 9 (4.9%) admitted for CDI recurrence. These patients accounted for 46 all-cause and 12 rCDI-related hospitalization events, with 3 patients each being hospitalized twice for CDI recurrence."
Clinical • Infectious Disease
|
|
Paul Feuerstadt MD FACG 1; Jessica R.. Allegretti MD MPH FACG 2; Erik R.. Dubberke MD 3; Alpesh N.. Amin MD MBA 4; James Sianis PharmD 5; Dina Hot PhD 6; Dianne Nguyen MD 5
|